CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

BridgeBio Pharma (BBIO) Wins FDA Review For Encaleret In ADH1

RegulatoryEncaleretPositive
AI Analysis

Summary

BridgeBio Pharma received FDA review acceptance for Encaleret in ADH1 indication. The regulatory milestone advances the company's development program.

Outcome Details

FDA review win for Encaleret in ADH1

Importance:6/10
Sentiment:
0.60
FDAregulatoryencaleretADH1
Related Companies

Read the original article

Published by yahoo_finance on August 4, 2026 1:11 AM

Read Original